These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36070850)

  • 1. Prediction of the response to photodynamic therapy in patients with chronic central serous chorioretinopathy based on optical coherence tomography using deep learning.
    Fernández-Vigo JI; Gómez Calleja V; de Moura Ramos JJ; Novo-Bujan J; Burgos-Blasco B; López-Guajardo L; Donate-López J; Ortega-Hortas M
    Photodiagnosis Photodyn Ther; 2022 Dec; 40():103107. PubMed ID: 36070850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Retinochoroidal Vascular and Structural Changes after Half-Dose Photodynamic Therapy versus Half-Fluence Photodynamic Therapy Based on Optical Coherence Tomography Angiography in Eyes with Chronic Central Serous Chorioretinopathy.
    Karasu B; Akbas YB; Aykut A; Celebi ARC
    Ophthalmologica; 2022; 245(4):323-334. PubMed ID: 35249031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fuji sign: Prevalence and predictive power to photodynamic therapy in chronic central serous chorioretinopathy.
    Pérez-García P; Oribio-Quinto C; Gómez-Calleja V; Moreno-Morillo FJ; Burgos-Blasco B; Fernández-Vigo JI
    Photodiagnosis Photodyn Ther; 2023 Jun; 42():103316. PubMed ID: 36746235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY-GUIDED PHOTODYNAMIC THERAPY FOR ACUTE CENTRAL SEROUS CHORIORETINOPATHY.
    Hu J; Qu J; Li M; Sun G; Piao Z; Liang Z; Yao Y; Sadda S; Zhao M
    Retina; 2021 Jan; 41(1):189-198. PubMed ID: 32343102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subretinal fluid morphology in chronic central serous chorioretinopathy and its relationship to treatment: a retrospective analysis on PLACE trial data.
    Subhi Y; Bjerager J; Boon CJF; van Dijk EHC
    Acta Ophthalmol; 2022 Feb; 100(1):89-95. PubMed ID: 33998168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of an additional photodynamic therapy session after multiple failed PDT treatments in chronic central serous chorioretinopathy.
    Moreno-Morillo FJ; Fernández-Vigo JI; Burgos-Blasco B; Moriche-Carretero M; López-Guajardo L; Donate-López J
    Photodiagnosis Photodyn Ther; 2022 Sep; 39():102953. PubMed ID: 35690322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphological integrity of the outer retinal layers and visual prognosis in chronic central serous chorioretinopathy after half-dose photodynamic therapy: a qualitative SD-OCT analysis.
    Gobeka HH; Mentes J; Nalcaci S; Oztas Z; Cay Y
    Lasers Med Sci; 2022 Dec; 38(1):9. PubMed ID: 36539551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Photodynamic therapy in chronic central serous chorioretinopathy with subretinal fluid outside the fovea.
    van Dijk EHC; Dijkman G; Boon CJF
    Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):2029-2035. PubMed ID: 28674835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. INSTRUMENTAL DIFFERENCE IN ASSESSING CHOROIDAL HYPERPERMEABILITY AND PHOTODYNAMIC THERAPY IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Lee SM; Kwon HJ; Park SW; Lee JE; Byon IS
    Retina; 2019 Jul; 39(7):1361-1369. PubMed ID: 29554076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy.
    van Rijssen TJ; van Dijk EHC; Dijkman G; Boon CJF
    Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1395-1402. PubMed ID: 29732468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Outcomes of Full-Fluence and Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
    Son BK; Kim K; Kim ES; Yu SY
    Ophthalmologica; 2019; 241(2):105-115. PubMed ID: 30110697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing Half-Dose Photodynamic Therapy with Subthreshold Micropulse Laser for the Treatment of Central Serous Chorioretinopathy.
    Brelen ME; Ho M; Li S; Ng DSC; Yip YWY; Lee WS; Chen LJ; Young AL; Tham CC; Pang CP
    Ophthalmol Retina; 2024 May; 8(5):490-498. PubMed ID: 37956794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the changes in choroidal macular anastomoses after photodynamic therapy and in the follow-up of central serous chorioretinopathy by en face optical coherence tomography.
    Oribio-Quinto C; Alarcón-García AD; Fuentes JE; Fernández-Vigo JI
    Photodiagnosis Photodyn Ther; 2023 Sep; 43():103719. PubMed ID: 37487812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of half-dose versus half-fluence versus standard photodynamic therapy in chronic central serous chorioretinopathy.
    Altinel MG; Kanra AY; Totuk OMG; Ardagil A; Kabadayi K
    Photodiagnosis Photodyn Ther; 2021 Mar; 33():102081. PubMed ID: 33157327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy.
    Lim JI; Glassman AR; Aiello LP; Chakravarthy U; Flaxel CJ; Spaide RF;
    Ophthalmology; 2014 May; 121(5):1073-8. PubMed ID: 24439758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
    Matušková V; Vysloužilová D; Uher M
    Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between the outcomes of fluorescein angiography-guided and indocyanine green angiography-guided half-time photodynamic therapy for central serous chorioretinopathy.
    Hayashida M; Miki A; Honda S; Nakamura M
    Photodiagnosis Photodyn Ther; 2020 Sep; 31():101955. PubMed ID: 32818640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crossover to Half-Dose Photodynamic Therapy or Eplerenone in Chronic Central Serous Chorioretinopathy Patients.
    Feenstra HMA; van Dijk EHC; van Rijssen TJ; Tsonaka R; Diederen RMH; Schlingemann RO; Hoyng CB; Boon CJF
    Ophthalmol Retina; 2022 Oct; 6(10):930-938. PubMed ID: 35470085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.
    Sheptulin V; Purtskhvanidze K; Roider J
    Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2027-2034. PubMed ID: 30097783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
    Smretschnig E; Ansari-Shahrezaei S; Hagen S; Glittenberg C; Krebs I; Binder S
    Retina; 2013 Feb; 33(2):316-23. PubMed ID: 23314238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.